Skip to main content

Cantor Fitzgerald Sticks to Their Buy Rating for Innoviva (INVA)

Tipranks - Tipranks - Tue Dec 16, 2025

In a report released yesterday, Steven Seedhouse from Cantor Fitzgerald maintained a Buy rating on Innoviva, with a price target of $31.00.

Claim 50% Off TipRanks Premium and Invest with Confidence

According to TipRanks, Seedhouse is a 5-star analyst with an average return of 12.5% and a 44.00% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Innoviva, and Xencor.

Currently, the analyst consensus on Innoviva is a Moderate Buy with an average price target of $32.00.

See Insiders’ Hot Stocks on TipRanks >>

Based on Innoviva’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $107.8 million and a net profit of $89.91 million. In comparison, last year the company earned a revenue of $89.51 million and had a net profit of $1.21 million

Read More on INVA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).